Positive News SentimentPositive NewsNASDAQ:DMAC DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free DMAC Stock Alerts $2.85 -0.18 (-5.94%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$2.85▼$2.9650-Day Range$2.58▼$3.2352-Week Range$1.46▼$4.75Volume36,527 shsAverage Volume38,617 shsMarket Capitalization$108.16 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get DiaMedica Therapeutics alerts: Email Address DiaMedica Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside145.6% Upside$7.00 Price TargetShort InterestBearish0.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.12 out of 5 starsMedical Sector815th out of 947 stocksPharmaceutical Preparations Industry373rd out of 432 stocks 3.5 Analyst's Opinion Consensus RatingDiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, DiaMedica Therapeutics has a forecasted upside of 145.6% from its current price of $2.85.Amount of Analyst CoverageDiaMedica Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.52% of the outstanding shares of DiaMedica Therapeutics have been sold short.Short Interest Ratio / Days to CoverDiaMedica Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in DiaMedica Therapeutics has recently increased by 3.70%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDiaMedica Therapeutics does not currently pay a dividend.Dividend GrowthDiaMedica Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DMAC. Previous Next 2.7 News and Social Media Coverage News SentimentDiaMedica Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for DMAC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added DiaMedica Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of DiaMedica Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 6.42% of the stock of DiaMedica Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of DiaMedica Therapeutics is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DiaMedica Therapeutics is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaMedica Therapeutics has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About DiaMedica Therapeutics Stock (NASDAQ:DMAC)DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More DMAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DMAC Stock News HeadlinesMarch 6, 2024 | ca.finance.yahoo.comTryp Therapeutics Inc. (TRYP.CN)February 9, 2024 | benzinga.comDiaMedica Therapeutics Stock (NASDAQ:DMAC) Dividends: History, Yield and DatesMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.January 29, 2024 | finance.yahoo.comDiaMedica Therapeutics Announces Poster Presentation at International Stroke ConferenceJanuary 7, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%December 11, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn SituationNovember 15, 2023 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Diamedica Therapeutics (DMAC), Abivax SA Sponsored ADR (ABVX)March 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… November 14, 2023 | finance.yahoo.comQ3 2023 DiaMedica Therapeutics Inc Earnings CallNovember 14, 2023 | gurufocus.comDiaMedica Therapeutics Inc. (DMAC) Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | finance.yahoo.comDiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$20.2mNovember 13, 2023 | msn.comDiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.01November 13, 2023 | finance.yahoo.comDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial ResultsNovember 10, 2023 | benzinga.comEarnings Outlook For DiaMedica TherapeuticsNovember 9, 2023 | finance.yahoo.comDiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023November 6, 2023 | finance.yahoo.comDiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023September 12, 2023 | finance.yahoo.comDiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology OfficerSeptember 6, 2023 | finance.yahoo.comDiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth ConferenceAugust 31, 2023 | finance.yahoo.comIs DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?August 15, 2023 | finance.yahoo.comQ2 2023 DiaMedica Therapeutics Inc Earnings CallAugust 14, 2023 | finance.yahoo.comDiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial ResultsAugust 8, 2023 | finance.yahoo.comDiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023July 18, 2023 | finance.yahoo.comDiaMedica Therapeutics to Attend the American Academy of Neurology Summer ConferenceJuly 6, 2023 | msn.comDiaMedica Therapeutics (DMAC) Price Target Increased by 11.11% to 8.50July 5, 2023 | msn.comThree (3) Stocks Under $10 That Insiders Are BuyingJune 26, 2023 | bizjournals.comDiaMedica Therapeutics raises $37.5 million for stroke and kidney treatmentSee More Headlines Receive DMAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2023Today3/19/2024Next Earnings (Estimated)3/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DMAC CUSIPN/A CIK1401040 Webwww.diamedica.com Phone(763) 496-5454FaxN/AEmployees16Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+145.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.01% Return on Assets-38.66% Debt Debt-to-Equity RatioN/A Current Ratio22.07 Quick Ratio22.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.20 per share Price / Book2.38Miscellaneous Outstanding Shares37,950,000Free Float35,487,000Market Cap$108.16 million OptionableOptionable Beta1.72 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Dietrich John Pauls MBA (Age 53)President, CEO & Director Comp: $736.79kMr. Scott Kellen CPA (Age 59)CFO & Company Secretary Comp: $447.02kDr. Kirsten L. Gruis M.D. (Age 51)M.S., Independent Consultant Comp: $519.82kDr. Ambarish Shah Ph.D.Chief Technology OfficerMr. Dominic R. Cundari (Age 73)Chief Commercial Officer Ms. Julie VanOrsdel Daves CCRPSenior VP of Clinical Development OperationsMr. David J. WambekeChief Business OfficerDr. Lorianne K. Masuoka M.D. (Age 63)Chief Medical Officer More ExecutivesKey CompetitorsCitius PharmaceuticalsNASDAQ:CTXRVistagen TherapeuticsNASDAQ:VTGNAcrivon TherapeuticsNASDAQ:ACRVSagimet BiosciencesNASDAQ:SGMTEton PharmaceuticalsNASDAQ:ETONView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 13,382 shares on 3/11/2024Ownership: 2.114%Vanguard Group Inc.Bought 13,382 shares on 2/15/2024Ownership: 2.114%Paragon Associates & Paragon Associates II Joint VentureBought 30,000 shares on 2/15/2024Ownership: 1.318%Citadel Advisors LLCBought 800 shares on 2/15/2024Ownership: 0.000%Northern Trust CorpBought 43,933 shares on 2/13/2024Ownership: 0.352%View All Insider TransactionsView All Institutional Transactions DMAC Stock Analysis - Frequently Asked Questions Should I buy or sell DiaMedica Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DMAC shares. View DMAC analyst ratings or view top-rated stocks. What is DiaMedica Therapeutics' stock price target for 2024? 1 equities research analysts have issued 1-year price targets for DiaMedica Therapeutics' stock. Their DMAC share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 145.6% from the stock's current price. View analysts price targets for DMAC or view top-rated stocks among Wall Street analysts. How have DMAC shares performed in 2024? DiaMedica Therapeutics' stock was trading at $2.84 at the beginning of 2024. Since then, DMAC shares have increased by 0.4% and is now trading at $2.85. View the best growth stocks for 2024 here. When is DiaMedica Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our DMAC earnings forecast. How were DiaMedica Therapeutics' earnings last quarter? DiaMedica Therapeutics Inc. (NASDAQ:DMAC) posted its quarterly earnings results on Tuesday, March, 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.14). During the same quarter last year, the business posted ($0.10) earnings per share. What other stocks do shareholders of DiaMedica Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE). When did DiaMedica Therapeutics IPO? (DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. Who are DiaMedica Therapeutics' major shareholders? DiaMedica Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.11%), Vanguard Group Inc. (2.11%), Paragon Associates & Paragon Associates II Joint Venture (1.32%), Northern Trust Corp (0.35%), Avantax Advisory Services Inc. (0.03%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David J Wambeke, Dietrich John Pauls, Harry W Alcorn Jr, Koch Thomas Von, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View institutional ownership trends. How do I buy shares of DiaMedica Therapeutics? Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DMAC) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.